Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

European recommended approval of Remicade for treatment of psoriatic arthritis

European recommended approval of Remicade for treatment of psoriatic arthritis

Cost differences of methotrexate and cyclosporine to treat psoriasis neglible

Cost differences of methotrexate and cyclosporine to treat psoriasis neglible

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise

Enbrel therapy allowed more rheumatoid arthritis patients to achieve clinical remission

Enbrel therapy allowed more rheumatoid arthritis patients to achieve clinical remission

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

500,000 patients have now been treated with REMICADE® worldwide

500,000 patients have now been treated with REMICADE® worldwide

Drug duo prevents life-threatening condition in children undergoing stem cell transplant

Drug duo prevents life-threatening condition in children undergoing stem cell transplant

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis